Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

NORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground around the globe ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional Office in San Francisco, a major HIV drug maker ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...

Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary ...

Gilead Sciences (GILD) ended the recent trading session at $111.88, demonstrating a +0.54% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of ...